Frankfurt - Delayed Quote EUR

Biovica International AB (publ) (9II.F)

0.0504
0.0000
(0.00%)
At close: May 19 at 8:11:52 AM GMT+2
Currency in SEK All numbers in thousands
Download
Breakdown
TTM
4/30/2024
4/30/2023
4/30/2022
4/30/2021
Total Revenue
8,186
7,290
3,384
2,045
2,077
Cost of Revenue
1,307
413
-1,233
-2,621
-3,193
Gross Profit
6,879
6,877
4,617
4,666
5,270
Operating Expense
115,394
134,507
115,541
65,965
46,849
Operating Income
-108,515
-127,630
-110,924
-61,299
-41,579
Net Non Operating Interest Income Expense
-1,426
870
-10
-78
795
Pretax Income
-106,576
-124,136
-110,680
-59,991
-39,386
Tax Provision
-187
687
-187
12
96
Net Income Common Stockholders
-106,388
-124,823
-110,492
-60,003
-39,483
Diluted NI Available to Com Stockholders
-106,388
-124,823
-110,492
-60,003
-39,483
Basic EPS
-1.22
-2.14
-3.17
-2.09
-1.38
Diluted EPS
-1.22
-2.14
-3.17
-2.09
-1.38
Basic Average Shares
87,998.5390
58,408.0990
34,828.2070
28,756.2820
28,720.9090
Diluted Average Shares
87,998.5390
58,408.0990
34,828.2070
28,756.2820
29,421.2870
Total Operating Income as Reported
-106,989
-126,845
-110,457
-60,101
-40,181
Total Expenses
116,701
134,920
114,308
63,344
43,656
Net Income from Continuing & Discontinued Operation
-106,388
-124,823
-110,492
-60,003
-39,483
Normalized Income
-106,388
-124,823
-110,574.8598
-60,901.8080
-40,411.9800
Interest Income
-688
1,159
271
0
855
Interest Expense
738
289
281
78
60
Net Interest Income
-1,426
870
-10
-78
795
EBIT
-105,838
-123,847
-110,399
-59,913
-39,326
EBITDA
-96,786
-114,418
-102,185
-53,474
-33,184
Reconciled Cost of Revenue
1,307
413
-1,233
-2,621
-3,193
Reconciled Depreciation
9,052
9,429
8,214
6,439
6,142
Net Income from Continuing Operation Net Minority Interest
-106,388
-124,823
-110,492
-60,003
-39,483
Total Unusual Items Excluding Goodwill
0
0
83
1,132
1,170
Total Unusual Items
0
0
83
1,132
1,170
Normalized EBITDA
-96,786
-114,418
-102,268
-54,606
-34,354
Tax Rate for Calcs
0
0.0002
0
0.0002
0.0002
Tax Effect of Unusual Items
0
0
0.1402
233.1920
241.0200
4/30/2021 - 12/15/2020

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

PHGN.BE Pharming Group
0.8505
+2.72%
 
ACTI.ST Active Biotech AB (publ)
0.1172
-6.09%
 
ONCO.ST Oncopeptides AB (publ)
1.9980
-0.10%
 
XBRANE.ST Xbrane Biopharma AB (publ)
0.2680
+5.10%
 
PHAR Pharming Group N.V.
9.31
-5.67%
 
ZEAL.CO Zealand Pharma A/S
416.00
-0.26%
 
RCKT Rocket Pharmaceuticals, Inc.
6.45
-0.77%
 
PLX Protalix BioTherapeutics, Inc.
1.6800
+0.60%
 
IVVD Invivyd, Inc.
0.7756
-0.14%
 
IBRX ImmunityBio, Inc.
2.8000
-1.41%